SEQUA.BR
Strong SellHot AirSequana Medical NV · Healthcare · Belgium · $54M · Avg Vol: $0/d
Hot Air: Rising on momentum alone: weak business, rich price.
ABOUT SEQUANA MEDICAL NV
Read
Sequana Medical NV is a commercial-stage medical device company developing innovative fluid management solutions for patients suffering from liver disease, heart failure, and cancer. The company core product, the alfapump, is a unique, fully implantable, wireless-charging pump system that automatically removes excess fluid from the abdomen into the bladder. It operates as a specialized medical technology player addressing significant unmet clinical needs in chronic fluid overload conditions.
FINANCIAL SUMMARY (EUR)
| Year | 2021 | 2022 | 2023 | 2024 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0.4M | 0.9M | 0.7M | 0.1M | -34.2% | — |
| EPS (EUR) | -0.31 | -0.41 | -0.44 | -1.22 | — | -1.23 |
| Shares | 78.2M | 78.2M | 78.2M | 44.4M | -43.2% | — |
| Debt | 8.1M | 17.6M | 17.5M | 40.1M | 70.6% | 41.4M |
| Equity | -0.8M | -2.2M | -19.5M | -44.4M | — | — |
| Op CF | -23.6M | -27.5M | -29.1M | -20.3M | — | -17.6M |
| Inv CF | -0.3M | -0.7M | -0.7M | -99.8K | — | — |
| Fin CF | 22.4M | 37.3M | 13.5M | 21.6M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SEQUA.BR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SEQUA.BR | Sequana Medical NV(you) | $54M | 13 | Strong Sell |
| IBAB.BR | Ion Beam Applications SA | $567M | 71 | Buy |
| MDXH | MDxHealth SA | $69M | 13 | Strong Sell |
| HYL.BR | Hyloris Pharmaceuticals SA | $143M | 14 | Strong Sell |
| NYXH | Nyxoah SA | $163M | 10 | Strong Sell |
| AGMB | AgomAb Therapeutics NV | $649M | 14 | Strong Sell |
| TUB.BR | Financière de Tubize SA | $9.6B | 29 | Sell |
| LKFT | Lakefront Biotherapeutics NV | $1.9B | 68 | Buy |
| FAGR.BR | Fagron NV | $1.9B | 83 | Strong Buy |
| UCB.BR | UCB SA | $47.8B | 79 | Buy |
Peer medians: ROE 5.0% · P/E 18.4x · Gross margin 60.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.